-+ 0.00%
-+ 0.00%
-+ 0.00%

Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx

PUBT·05/18/2026 21:01:19
Listen to the news
Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx
  • Telix completed enrolment in its Phase 1 IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma.
  • Interim safety observations have been positive, with dosing reaching the study maximum without dose-limiting toxicities; final confirmation of the maximum tolerated dose will come later when the trial completes, so results have not yet been formally presented.
  • The update supports continued development of TLX101-Tx for first-line glioblastoma, a potential expansion beyond its ongoing Phase 3 IPAX BrIGHT program in recurrent disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181700PRIMZONEFULLFEED9721955) on May 18, 2026, and is solely responsible for the information contained therein.